Fig. 2From: Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patientsKaplan-Meier survival estimates for PFS—full analysis set. Median PFS for the monotherapy and combined therapy groups was 5.40 months (95 % CI 2.90, 9.80) and 7.90 months (95 % CI 6.10, 9.80), respectivelyBack to article page